MARY HETTICH-KELLY: Open Payments
NPI 1790810257 · HYANNIS, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$510 in 18 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $510
Food & beverage: $510
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 6 | $193 |
| Otsuka America Pharmaceutical, Inc. | 2 | $65 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $64 |
| E.R. Squibb & Sons, L.L.C. | 2 | $60 |
| Lundbeck LLC | 1 | $28 |
| ABBVIE INC. | 1 | $23 |
| Alkermes, Inc. | 1 | $23 |
| Luye Pharma (USA) Ltd. | 1 | $21 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
Products named: FANAPT, REXULTI, CAPLYTA, COBENFY, VRAYLAR, ARISTADA, ERZOFRI EXTENDED-RELEASE, INVEGA SUSTENNA.
Industry payments across MA — which companies pay providers there.
